Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma Company N.V. Ordinary Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
18.9 USD 0.01 ( 0.05%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1689832
Market Cap
1746.62M

Momentum Score

…

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
18.50
Low
19.39
High
52 Week Price Range
5.63
Low
26.35
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

NewAmsterdam Pharma Company N.V. is a Netherlands‑domiciled, publicly listed pharmaceutical company; public disclosures about its specific programs and revenues are limited. Its long‑term growth may depend on successful clinical development, regulatory approvals, licensing or commercialization and access to capital, which could make the name attractive to investors who prioritize potential upside from milestone‑driven biotech development.

Primary investment risks include clinical or regulatory setbacks, the need for additional financing that may dilute shareholders, competitive and market access pressures, and operational execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
18.89
Dividend Yield
-
Revenue TTM
6.86M
Revenue Per Share
0.08
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-54.33%
Net Debt
-340.39M
ROCE
-22.73%
Diluted EPS TTM
-2.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -78.05M -28.60M -5.75M
Net income -148.88M -28.82M -6.09M
Selling general administrative 18.14M 3.94M 1.37M
Selling and marketing expenses 3.75M 0.71M 0.01M
Gross profit 97.50M - -
Reconciled depreciation 0.07M 0.01M 0.00M
Ebit -67.56M -29.83M -5.43M
Ebitda -6.88M -29.81M -5.43M
Depreciation and amortization 60.68M 0.01M 0.00M
Operating income -67.56M -29.83M -5.43M
Other operating expenses 104.46M 29.84M 5.43M
Interest expense 0.27M 0.22M 0.34M
Tax provision 0.00M 0.00M 0.00M
Interest income 0.01M 0.01M 0.00M
Net interest income -0.26M -0.21M -0.34M
Income tax expense 70.83M 0.22M 0.34M
Total revenue 97.50M 0.00M 0.00M
Total operating expenses 104.46M 29.84M 5.43M
Total other income expense net -10.49M 1.23M -0.32M
Net income from continuing ops -78.05M -28.60M -5.75M
Net income applicable to common shares - -28.60M -5.75M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 347.10M 531.58M 59.78M 9.23M
Intangible assets 0.17M - - -
Other current assets 6.34M - 1.49M 1.36M
Total liab 58.70M 47.06M 9.99M 12.81M
Total stockholder equity 288.39M 484.52M 49.79M -3.58M
Other current liab 23.97M 11.28M 0.00M 0.76M
Common stock 10.17M 599.19M 83.88M 2.50M
Capital stock 10.17M 599.19M 83.88M 2.50M
Retained earnings -316.97M -119.36M -34.68M -6.08M
Other assets - - 0.72M -
Cash 340.45M 438.52M 53.09M 7.86M
Total current liabilities 49.90M 35.46M 9.88M 12.81M
Current deferred revenue 8.94M 13.01M 3.61M -
Net debt -340.39M -438.40M -52.93M 3.79M
Short term debt 0.06M 0.06M 0.05M 11.65M
Short long term debt - - - 11.65M
Short long term debt total 0.06M 0.12M 0.16M 11.65M
Other stockholder equity 273.80M - 0.59M -
Property plant equipment - - 0.19M 0.01M
Total current assets 346.79M 448.13M 58.87M 9.22M
Net tangible assets - - 49.79M -3.58M
Net receivables 1.88M 1.94M 4.29M -
Inventory -1.88M - - -
Accounts payable 16.92M 11.11M 6.22M 0.40M
Accumulated other comprehensive income 4.42M 4.69M 0.59M -
Non currrent assets other 0.04M 0.15M 0.72M -
Non current assets total 0.31M 83.45M 0.91M 0.01M
Capital lease obligations 0.06M 0.12M 0.16M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments 0.71M -0.02M -0.01M
Change to liabilities - 8.25M 0.83M
Total cashflows from investing activities - -0.02M -0.01M
Net borrowings - -0.01M 11.32M
Total cash from financing activities 375.18M 68.99M 11.32M
Change to operating activities - -4.42M -1.36M
Net income -78.05M -28.60M -5.75M
Change in cash 385.43M 45.23M 5.36M
Begin period cash flow 53.09M 7.86M 2.50M
End period cash flow 438.52M 53.09M 7.86M
Total cash from operating activities 7.97M -25.16M -5.97M
Issuance of capital stock 377.78M 69.00M 0.00M
Depreciation 0.07M 0.01M 0.00M
Other cashflows from financing activities -2.53M -0.02M -0.01M
Change to netincome - -0.40M 0.31M
Capital expenditures 0.01M 0.02M 0.01M
Change in working capital 11.46M 3.82M -0.53M
Stock based compensation 3.92M 1.05M 0.00M
Other non cash items 70.57M -0.01M 0.31M
Free cash flow 7.96M -25.18M -5.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares		 0.01
0.05%		 18.90 - - 124.81 6.13 101.29 -8.07
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

NewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Gooimeer 2-35, Naarden, Netherlands, 1411 DC

31 35 206 2971

https://www.newamsterdampharma.com

40

Name Title Year Born
Dr. Michael Harvey Davidson FACC, Facc., Facp., M.D. CEO, Pres, Exec. Board Member & Director 1957
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer & Member of Exec. Board 1954
Ms. Louise Kooij CFO, Treasurer, Member of Exec. Board & Director NA
Mr. Douglas F. Kling COO, VP & Director 1973
Mr. Jim Jacobson Chief Legal Officer & Sec. NA
Ms. Lina Gugucheva Chief Bus. Officer NA
Dr. Sheng Cui Ph.D. VP & Head of Chemistry Manufacturing and Controls (CMC) NA
Ms. Annie Neild VP & Head of Regulatory Affairs NA
Dr. Michael Harvey Davidson FACC, Facp., M.D. CEO, President, Executive Board Member & Director 1956
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. Founder, Chief Scientific Officer, Member of Executive Board & Director 1954

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…